Cardiol Therapeutics Inc. (CRDR) is a leader in the production of pharmaceutical cannabidiol (CBD) and the development of innovative cannabidiol medicines for heart diseases. The company is a Canadian-based biotechnology company that pioneers the research and commercial production of premium, pharmaceutical-grade CBD and pursues the clinical development of pure CBD therapies for severe cardiovascular diseases.
Primarily, Cardiol Therapeutics focuses on the heart failure market, which is the leading cause of death and hospitalization in North America, with associated annual healthcare costs exceeding $30 billion. Cardiol's primary drug candidate, CardiolRx™, is designed to be the safest and most consistent CBD formulation available.
Cardiol's pharmaceutical strategy is to commercially produce CardiolRx™, a pharmaceutically-produced cannabidiol formulation that does not contain THC (the psychoactive component of cannabis) for distribution in the billion-dollar market for medicinal cannabinoids in Canada and for pursuing breakthrough, orphan drug applications for acute myocarditis, which is an inflammation of the heart muscle, and other causes of heart failure worldwide.
In addition to pharmaceutical CBD, Cardiol also develops nanotherapeutics to treat heart failure. Their patented nanotechnology is used to deliver anti-inflammatory drugs directly to the inflamed heart tissue associated with heart diseases, enhancing the treatment's efficacy while reducing side effects.
Cardiol is driven by a team of scientific and medical professionals, experienced in pharmaceutical product development and commercialization and passionate about pioneering new paths in cardiovascular medicine. The company believes in research, innovation, and developing new therapies that could potentially change the prognosis for thousands of heart disease patients around the world.
In addition to their commitment to groundbreaking medical advancements, Cardiol Therapeutics places significant importance on social responsibility. They operate in line with Good Manufacturing Practices, ensuring the highest quality products, and they are committed to the ethical and sustainable sourcing of their ingredients.
All in all, Cardiol Therapeutics Inc. (CRDL) is committed to the research and development of innovative therapies that have the potential to change lives for the better and strives to continue to deliver high-quality, pharmaceutically-produced CBD products for medical use.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Tejara Capital Ltd has disclosed a 5.3% ownership stake in Cardiol Therapeutics (NASDAQ: CRDL), holding 6,382,551 Class A common shares. This investment is classified as passive, indicating no intention to influence or change control of the biotechnology firm. The ownership report was signed by Miyan Mansur Mannan as director on September 23, 2026, and is filed on a Schedule 13G/A under Rule 13d-1(b).
Cardiol Therapeutics Inc. (TSX:CRDL) is gaining investor attention following a recent disclosure that the company reported over seven million U.S. dollars in warrant exercise proceeds. This financial boost extends its cash runway as it approaches a pivotal trial readout. The news provides a fresh, company-specific catalyst for healthcare stock observers, allowing them to assess the company's financial health and compare its performance against other Canadian healthcare, biotech, and life-sciences firms.
Cardiol Therapeutics Inc. Class A (TSX:CRDL) experienced a 6.86% decline on September 15, 2026, indicating significant selling pressure and a shift in investor sentiment. While the specific catalyst for the drop remains unconfirmed, the article advises investors to scrutinize company disclosures rather than assuming a permanent change in fundamentals, as volatility is common for smaller-cap biopharmaceutical companies. The company's business model relies on advancing cardiovascular therapeutic candidates through clinical trials, funded by equity financing.
Cardiol Therapeutics Inc. (TSX: CRDL) saw its shares drop by 12.34% due to heightened biotech risk and clinical uncertainty. The company, focused on cardiovascular disease therapies, is heavily reliant on the success of its lead candidate, CardiolRx, currently in Phase 3 trials. Investor sentiment is sensitive to trial outcomes, funding needs, and the broader challenging biotechnology environment, leading to increased volatility for the stock.
Cardiol Therapeutics Inc. (TSX:CRDL) saw its shares climb over 10% due to increasing investor optimism surrounding its pivotal MAVERIC Phase III clinical trial for CardiolRx, a drug treating recurrent pericarditis. The company's scientific foundation has been strengthened by recent peer-reviewed publications, validating CardiolRx across various inflammatory heart diseases. While the investment case offers substantial clinical optionality, it is exposed to risks associated with trial outcomes, regulatory hurdles, and commercialization challenges.
Wall Street Zen has upgraded Cardiol Therapeutics (NASDAQ:CRDL) from a "Sell" to a "Hold" rating, aligning with the overall average "Hold" rating from analysts and an $8.50 price target. CRDL shares rose 5.3% to $1.80, with a market cap of $208.6 million, and the company reported a quarterly EPS of -$0.04, outperforming consensus estimates. Institutional investors collectively own 12.49% of the company, which focuses on developing immunomodulatory treatments for cardiovascular disease.
Cardiol Therapeutics (NASDAQ:CRDL) recently announced its quarterly earnings, reporting an EPS of ($0.04), which surpassed analyst expectations of ($0.09) by $0.05. Following the announcement, the company's shares increased by 1.3% to $1.52, with a market capitalization of approximately $176.15 million. Analyst sentiment for CRDL is mixed, with a consensus "Hold" rating and an $8.50 price target from two Buy and one Sell rating.
Cardiol Therapeutics (TSX:CRDL) is a clinical-stage life sciences company focused on developing therapies for cardiovascular conditions, with its research strategy centered on addressing unmet therapeutic needs in this area. The company's future hinges on clinical execution, regulatory developments, and the quality of its trial evidence. Key factors influencing its outlook include clinical trial updates, regulatory interactions, and scientific presentations at industry conferences, all of which will determine the progression of its pipeline towards advanced development and potential commercialization.